|
|
Volumn 27, Issue 6, 1998, Pages 1386-1387
|
|
Editorial response: What is the relevance of antiretroviral therapy that does not include protease inhibitors?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CD4 ANTIGEN;
DIDANOSINE;
LAMIVUDINE;
PROTEINASE INHIBITOR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
STAVUDINE;
ZALCITABINE;
ZIDOVUDINE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
CANADA;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
DRUG COST;
EDITORIAL;
HEALTH INSURANCE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LYMPHOCYTE COUNT;
OPPORTUNISTIC INFECTION;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
AIDS RELATED COMPLEX;
DRUG COMBINATION;
FEMALE;
INCIDENCE;
MALE;
NOTE;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANTI-HIV AGENTS;
BRITISH COLUMBIA;
DRUG THERAPY, COMBINATION;
FEMALE;
HIV INFECTIONS;
HUMANS;
INCIDENCE;
MALE;
PROTEASE INHIBITORS;
|
|
EID: 0032254119
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/515031 Document Type: Editorial |
|
Times cited : (1)
|
|
References (23)
|
